$RLMD
RELMADA THERAPEUTICS, INC.

2024 Q3 Form 10-Q Financial Statement

#000121390024066111 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.86M $8.098M
YoY Change -3.11% -34.09%
% of Gross Profit
Research & Development $11.15M $10.72M
YoY Change 6.65% -21.97%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $23.01M $18.82M
YoY Change 1.39% -27.69%
Operating Profit -$23.01M -$18.82M
YoY Change 1.39% -27.69%
Interest Expense $1.283M $1.051M
YoY Change 85.92% 45.16%
% of Operating Profit
Other Income/Expense, Net $1.283M $1.051M
YoY Change 85.77% 45.16%
Pretax Income -$21.73M -$17.77M
YoY Change -1.25% -29.78%
Income Tax
% Of Pretax Income
Net Earnings -$21.73M -$17.77M
YoY Change -1.25% -29.78%
Net Earnings / Revenue
Basic Earnings Per Share -$0.72 -$0.59
Diluted Earnings Per Share -$0.72 -$0.59
COMMON SHARES
Basic Shares Outstanding 30.17M shares 30.17M shares
Diluted Shares Outstanding 30.17M shares 30.17M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.12M $70.44M
YoY Change -49.09% -40.57%
Cash & Equivalents $1.484M $2.086M
Short-Term Investments $52.63M $68.35M
Other Short-Term Assets $1.585M $537.5K
YoY Change -43.4% -84.53%
Inventory
Prepaid Expenses $1.585M $537.5K
Receivables
Other Receivables
Total Short-Term Assets $55.70M $70.97M
YoY Change -48.94% -41.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.98K $53.63K
YoY Change -53.95% 55.03%
Total Long-Term Assets $21.98K $53.63K
YoY Change -53.95% 55.03%
TOTAL ASSETS
Total Short-Term Assets $55.70M $70.97M
Total Long-Term Assets $21.98K $53.63K
Total Assets $55.72M $71.03M
YoY Change -48.95% -41.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.346M $4.175M
YoY Change -17.89% -13.99%
Accrued Expenses $5.741M $5.362M
YoY Change 3.16% -8.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.087M $9.537M
YoY Change -3.98% -10.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.087M $9.537M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $8.099M $9.537M
YoY Change -3.58% -10.89%
SHAREHOLDERS EQUITY
Retained Earnings -$622.2M -$600.5M
YoY Change 16.14% 16.89%
Common Stock $30.17K $30.17K
YoY Change 0.25% 0.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.63M $61.49M
YoY Change
Total Liabilities & Shareholders Equity $55.72M $71.03M
YoY Change -48.95% -41.8%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$21.73M -$17.77M
YoY Change -1.25% -29.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$16.66M -$13.26M
YoY Change 43.22% -0.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $16.14M $14.01M
YoY Change 318.23% -1316.79%
Cash From Investing Activities $16.14M $14.01M
YoY Change 318.23% -1316.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -89.60K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -16.66M -13.26M
Cash From Investing Activities 16.14M 14.01M
Cash From Financing Activities -89.60K 0.000
Net Change In Cash -602.5K 751.3K
YoY Change -92.25% -105.21%
FREE CASH FLOW
Cash From Operating Activities -$16.66M -$13.26M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30174202 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30153186 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Relmada Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5401931
dei Entity Address Address Line1
EntityAddressAddressLine1
2222 Ponce de Leon
dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Coral Gables
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33134
dei City Area Code
CityAreaCode
(786)
dei Local Phone Number
LocalPhoneNumber
629-1376
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
RLMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30174202 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2086260 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4091568 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
68351069 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
92232292 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
537522 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1185057 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
70974851 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
97508917 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53625 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43125 usd
CY2024Q2 us-gaap Assets
Assets
71028476 usd
CY2023Q4 us-gaap Assets
Assets
97552042 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4174568 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3506009 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5362280 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8688791 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9536848 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12194800 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30174202 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30174202 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30099203 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30099203 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
30174 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
30099 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
661960383 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
646229824 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-600498929 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-560902681 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
61491628 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
85357242 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71028476 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97552042 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10721089 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13740205 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24026395 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29601215 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8097695 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12286521 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17780249 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24579120 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
18818784 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
26026726 usd
us-gaap Operating Expenses
OperatingExpenses
41806644 usd
us-gaap Operating Expenses
OperatingExpenses
54180335 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18818784 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26026726 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-41806644 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-54180335 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
963013 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1363406 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2018901 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2571037 usd
CY2024Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
133114 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
186247 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-666708 usd
CY2024Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-45465 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-639634 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5248 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
651476 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1050662 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
723772 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2210396 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2555805 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-17768122 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25302954 usd
us-gaap Net Income Loss
NetIncomeLoss
-39596248 usd
us-gaap Net Income Loss
NetIncomeLoss
-51624530 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30174202 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30153186 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
85357242 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8295468 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
246747 usd
CY2024Q1 rlmd Adjustments To Additional Paid In Capital To Atm Fees
AdjustmentsToAdditionalPaidInCapitalToATMFees
-25000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-21828126 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
72046331 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7213419 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-17768122 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
61491628 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
140436302 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11354466 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26321576 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
125469192 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11169517 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25302954 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111335755 usd
us-gaap Net Income Loss
NetIncomeLoss
-39596248 usd
us-gaap Net Income Loss
NetIncomeLoss
-51624530 usd
us-gaap Share Based Compensation
ShareBasedCompensation
15508887 usd
us-gaap Share Based Compensation
ShareBasedCompensation
22523983 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
186247 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-666708 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5248 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
651476 usd
rlmd Gain On Settlement Of Fees
GainOnSettlementOfFees
-512432 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-637035 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-560931 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
668559 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-408320 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3326511 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1358091 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26299773 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29778363 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
8313312 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
45577832 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
32386030 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
84429644 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24072718 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38851812 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
246747 usd
rlmd Atm Fee
ATMFee
-25000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
221747 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2005308 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
9073449 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4091568 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5395905 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2086260 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14469354 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relmada Therapeutics, Inc. (Relmada or the Company) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. Relmada is also developing a proprietary, modified-release formulation of psilocybin (REL-P11) for metabolic indications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the Food and Drug Administration (FDA) and other governmental regulations and approval requirements.</p>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26299773 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-600498929 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2086260 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
68351069 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
92232292 usd
CY2024Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-45465 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5248 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-639634 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
651476 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.47
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14866047 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15511297 shares
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
86000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
365100 usd
CY2024Q2 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
349400 usd
CY2023Q4 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
695000 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
102100 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
125000 usd
CY2024Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
537500 usd
CY2023Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
1185100 usd
CY2024Q2 rlmd Accrued Research And Development
AccruedResearchAndDevelopment
4035700 usd
CY2023Q4 rlmd Accrued Research And Development
AccruedResearchAndDevelopment
5394700 usd
CY2024Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
240300 usd
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
174000 usd
CY2024Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
621600 usd
CY2023Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
2632400 usd
CY2024Q2 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
395000 usd
CY2023Q4 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
372200 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
69700 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
115500 usd
CY2024Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5362300 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
8688800 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1300000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.041 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y6M3D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39200000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M28D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17416192 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.99
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11183370 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
487434 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.1
rlmd Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y10M17D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
74999 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18407 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4757628 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13052592 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M7D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
352084 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8289638 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M8D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
44692 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
2381366 shares
CY2023Q4 rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
20.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
567911 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1813455 shares
CY2024Q2 rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
23.72
CY2024Q2 rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsVested
1722705 shares
CY2024Q2 rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Warrants Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityWarrantsVested
23.27
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
1700000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
0 usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15508900 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22524000 usd
rlmd Royalty Payments Percentage
RoyaltyPaymentsPercentage
0.02 pure
rlmd Royalties Received
RoyaltiesReceived
0.20 pure
rlmd Net Sales
NetSales
0.02 pure
us-gaap Payments For Fees
PaymentsForFees
45000 usd
rlmd Tiered Payments
TieredPayments
0.20 pure
us-gaap Taxes And Licenses
TaxesAndLicenses
45000 usd
CY2021Q3 us-gaap Entertainment License Agreement For Program Material Capitalized Cost
EntertainmentLicenseAgreementForProgramMaterialCapitalizedCost
12700000 usd
CY2021Q3 us-gaap Development In Process
DevelopmentInProcess
160000000 usd
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
11000 usd
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5M
CY2021Q3 rlmd Lessee Operating Sublease Option To Expired
LesseeOperatingSubleaseOptionToExpired
2021-12-31
CY2023Q1 us-gaap Payments For Rent
PaymentsForRent
14500 usd
CY2023Q1 us-gaap Lessee Operating Sublease Option To Terminate
LesseeOperatingSubleaseOptionToTerminate
November 30, 2023
CY2023Q4 us-gaap Payments For Rent
PaymentsForRent
12000 usd
CY2023Q4 rlmd Lessee Operating Sublease Option To Expired
LesseeOperatingSubleaseOptionToExpired
2024-05-31
CY2024Q2 us-gaap Payments For Rent
PaymentsForRent
10500 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
122100 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
137000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
69400 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
80900 usd
ecd Trd Arr Adoption Date
TrdArrAdoptionDate
On May 14, 2024
ecd Trd Arr Ind Name
TrdArrIndName
Charles Ence
ecd Trd Arr Ind Title
TrdArrIndTitle
Chief Accounting and Compliance Officer
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
ecd Trd Arr Duration
TrdArrDuration
P8M
CY2024Q2 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
174361 shares
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30099203 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30099203 shares
rlmd Gain On Settlement Of Fees
GainOnSettlementOfFees
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
rlmd Atm Fee
ATMFee
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
rlmd Share Based Compensation Arrangement By Share Basedd Payment Award Options Outstanding Granted Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBaseddPaymentAwardOptionsOutstandingGrantedAggregateIntrinsicValue
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
rlmd Share Based Compensation Arrangement By Share Baseed Payment Award Options Outstanding Forfeited Intrinsic Value
ShareBasedCompensationArrangementByShareBaseedPaymentAwardOptionsOutstandingForfeitedIntrinsicValue
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
rlmd Share Based Compensation Arrangement By Share Based Payment Award Options Outstandin Aggregate Intrinsic Value Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandinAggregateIntrinsicValueCancelled
usd
rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001553643

Files In Submission

Name View Source Status
0001213900-24-066111-index-headers.html Edgar Link pending
0001213900-24-066111-index.html Edgar Link pending
0001213900-24-066111.txt Edgar Link pending
0001213900-24-066111-xbrl.zip Edgar Link pending
ea0209311-10q_relmada.htm Edgar Link pending
ea020931101ex31-1_relmada.htm Edgar Link pending
ea020931101ex31-2_relmada.htm Edgar Link pending
ea020931101ex32-1_relmada.htm Edgar Link pending
ea020931101ex32-2_relmada.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ea0209311-10q_relmada_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlmd-20240630.xsd Edgar Link pending
Show.js Edgar Link pending
rlmd-20240630_cal.xml Edgar Link unprocessable
rlmd-20240630_def.xml Edgar Link unprocessable
rlmd-20240630_lab.xml Edgar Link unprocessable
rlmd-20240630_pre.xml Edgar Link unprocessable